Microbiome at the Frontier of Personalized Medicine

The genomic revolution promises to transform our approach to treat patients by individualizing treatments, reducing adverse events, and decreasing health care costs. The early advances using this have been realized primarily by optimizing preventive and therapeutic approaches in cancer using human g...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mayo Clinic proceedings 2017-12, Vol.92 (12), p.1855-1864
Hauptverfasser: Kashyap, Purna C., Chia, Nicholas, Nelson, Heidi, Segal, Eran, Elinav, Eran
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1864
container_issue 12
container_start_page 1855
container_title Mayo Clinic proceedings
container_volume 92
creator Kashyap, Purna C.
Chia, Nicholas
Nelson, Heidi
Segal, Eran
Elinav, Eran
description The genomic revolution promises to transform our approach to treat patients by individualizing treatments, reducing adverse events, and decreasing health care costs. The early advances using this have been realized primarily by optimizing preventive and therapeutic approaches in cancer using human genome sequencing. The ability to characterize the microbiome, which includes all the microbes that reside within and upon us and all their genetic elements, using next-generation sequencing allows us to now incorporate this important contributor to human disease into developing new preventive and therapeutic strategies. In this review we highlight the importance of the microbiome in all aspects of human disease, including pathogenesis, phenotype, prognosis, and response to treatment, as well as their role as diagnostic and therapeutic biomarkers. We provide a role for next-generation sequencing in both precise microbial identification of infectious diseases and characterization of microbial communities and their function. Taken together, the microbiome is emerging as an integral part of precision medicine approach as it not only contributes to interindividual variability in all aspects of a disease but also represents a potentially modifiable factor that is amenable to targeting by therapeutics.
doi_str_mv 10.1016/j.mayocp.2017.10.004
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5730337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A522584365</galeid><els_id>S0025619617307322</els_id><sourcerecordid>A522584365</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-f8ee45bebcd7978baf0e4660263819816448deaef6f3d4184e1789329a5be4b73</originalsourceid><addsrcrecordid>eNp9kU1rFTEUhoMo9lr9ByIDgriZab5nshFKsbXQUhe6DpnMmd5cZpJrkinUX29ub-2HC8kicPK853DyIPSe4IZgIo82zWxug902FJO2lBqM-Qu0IorTWgguX6IVxlTUkih5gN6ktMEYt0rx1-iAKoppAVeIXTobQ-_CDJXJVV5DdRqDzw5iFcbqO8QUvJncbxiqSxicdR7eolejmRK8u78P0c_Trz9OvtUXV2fnJ8cXtZW0zfXYAXDRQ2-HVrVdb0YMXEpMJeuI6ojkvBvAwChHNnDScSBtpxhVpoR437JD9GXfd7v0MwwWfI5m0tvoZhNvdTBOP3_xbq2vw40WLcOM7Rp8vm8Qw68FUtazSxamyXgIS9JEFZCyVnQF_fgPuglLLJvfUZIJKqkqVLOnrs0E2vkxlLm2nAFmZ4OH0ZX6saBUdJxJUQKfngTWYKa8TmFasgs-PQf5Hiw2UoowPqxJsN751hu99613vnfV4rvEPjz9oofQX8GPfwhF1E2xqpN14G1RGcFmPQT3_wl_AJ_DvAs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1976352629</pqid></control><display><type>article</type><title>Microbiome at the Frontier of Personalized Medicine</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kashyap, Purna C. ; Chia, Nicholas ; Nelson, Heidi ; Segal, Eran ; Elinav, Eran</creator><creatorcontrib>Kashyap, Purna C. ; Chia, Nicholas ; Nelson, Heidi ; Segal, Eran ; Elinav, Eran</creatorcontrib><description>The genomic revolution promises to transform our approach to treat patients by individualizing treatments, reducing adverse events, and decreasing health care costs. The early advances using this have been realized primarily by optimizing preventive and therapeutic approaches in cancer using human genome sequencing. The ability to characterize the microbiome, which includes all the microbes that reside within and upon us and all their genetic elements, using next-generation sequencing allows us to now incorporate this important contributor to human disease into developing new preventive and therapeutic strategies. In this review we highlight the importance of the microbiome in all aspects of human disease, including pathogenesis, phenotype, prognosis, and response to treatment, as well as their role as diagnostic and therapeutic biomarkers. We provide a role for next-generation sequencing in both precise microbial identification of infectious diseases and characterization of microbial communities and their function. Taken together, the microbiome is emerging as an integral part of precision medicine approach as it not only contributes to interindividual variability in all aspects of a disease but also represents a potentially modifiable factor that is amenable to targeting by therapeutics.</description><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.1016/j.mayocp.2017.10.004</identifier><identifier>PMID: 29202942</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Antibiotics ; Biomarkers ; Diabetes ; Diet ; Disease ; Disease prevention ; Ecosystems ; Feces ; Forecasts and trends ; Gastroenterology ; Gastrointestinal Microbiome - physiology ; Gastrointestinal Tract - microbiology ; Gene expression ; Genetic aspects ; Genome, Human ; Genomes ; Health aspects ; Humans ; Infectious diseases ; Irritable bowel syndrome ; Medicine ; Metabolism ; Metabolites ; Microbiomes ; Microbiota ; Microbiota (Symbiotic organisms) ; Next-generation sequencing ; Nutrition research ; Pathogenesis ; Phenotypes ; Precision Medicine ; Probiotics ; Prognosis ; Therapeutic applications</subject><ispartof>Mayo Clinic proceedings, 2017-12, Vol.92 (12), p.1855-1864</ispartof><rights>2017 Mayo Foundation for Medical Education and Research</rights><rights>Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</rights><rights>COPYRIGHT 2017 Frontline Medical Communications Inc.</rights><rights>Copyright Mayo Foundation for Medical Education and Research Dec 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-f8ee45bebcd7978baf0e4660263819816448deaef6f3d4184e1789329a5be4b73</citedby><cites>FETCH-LOGICAL-c627t-f8ee45bebcd7978baf0e4660263819816448deaef6f3d4184e1789329a5be4b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29202942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kashyap, Purna C.</creatorcontrib><creatorcontrib>Chia, Nicholas</creatorcontrib><creatorcontrib>Nelson, Heidi</creatorcontrib><creatorcontrib>Segal, Eran</creatorcontrib><creatorcontrib>Elinav, Eran</creatorcontrib><title>Microbiome at the Frontier of Personalized Medicine</title><title>Mayo Clinic proceedings</title><addtitle>Mayo Clin Proc</addtitle><description>The genomic revolution promises to transform our approach to treat patients by individualizing treatments, reducing adverse events, and decreasing health care costs. The early advances using this have been realized primarily by optimizing preventive and therapeutic approaches in cancer using human genome sequencing. The ability to characterize the microbiome, which includes all the microbes that reside within and upon us and all their genetic elements, using next-generation sequencing allows us to now incorporate this important contributor to human disease into developing new preventive and therapeutic strategies. In this review we highlight the importance of the microbiome in all aspects of human disease, including pathogenesis, phenotype, prognosis, and response to treatment, as well as their role as diagnostic and therapeutic biomarkers. We provide a role for next-generation sequencing in both precise microbial identification of infectious diseases and characterization of microbial communities and their function. Taken together, the microbiome is emerging as an integral part of precision medicine approach as it not only contributes to interindividual variability in all aspects of a disease but also represents a potentially modifiable factor that is amenable to targeting by therapeutics.</description><subject>Antibiotics</subject><subject>Biomarkers</subject><subject>Diabetes</subject><subject>Diet</subject><subject>Disease</subject><subject>Disease prevention</subject><subject>Ecosystems</subject><subject>Feces</subject><subject>Forecasts and trends</subject><subject>Gastroenterology</subject><subject>Gastrointestinal Microbiome - physiology</subject><subject>Gastrointestinal Tract - microbiology</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Genome, Human</subject><subject>Genomes</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Irritable bowel syndrome</subject><subject>Medicine</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Microbiomes</subject><subject>Microbiota</subject><subject>Microbiota (Symbiotic organisms)</subject><subject>Next-generation sequencing</subject><subject>Nutrition research</subject><subject>Pathogenesis</subject><subject>Phenotypes</subject><subject>Precision Medicine</subject><subject>Probiotics</subject><subject>Prognosis</subject><subject>Therapeutic applications</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1rFTEUhoMo9lr9ByIDgriZab5nshFKsbXQUhe6DpnMmd5cZpJrkinUX29ub-2HC8kicPK853DyIPSe4IZgIo82zWxug902FJO2lBqM-Qu0IorTWgguX6IVxlTUkih5gN6ktMEYt0rx1-iAKoppAVeIXTobQ-_CDJXJVV5DdRqDzw5iFcbqO8QUvJncbxiqSxicdR7eolejmRK8u78P0c_Trz9OvtUXV2fnJ8cXtZW0zfXYAXDRQ2-HVrVdb0YMXEpMJeuI6ojkvBvAwChHNnDScSBtpxhVpoR437JD9GXfd7v0MwwWfI5m0tvoZhNvdTBOP3_xbq2vw40WLcOM7Rp8vm8Qw68FUtazSxamyXgIS9JEFZCyVnQF_fgPuglLLJvfUZIJKqkqVLOnrs0E2vkxlLm2nAFmZ4OH0ZX6saBUdJxJUQKfngTWYKa8TmFasgs-PQf5Hiw2UoowPqxJsN751hu99613vnfV4rvEPjz9oofQX8GPfwhF1E2xqpN14G1RGcFmPQT3_wl_AJ_DvAs</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Kashyap, Purna C.</creator><creator>Chia, Nicholas</creator><creator>Nelson, Heidi</creator><creator>Segal, Eran</creator><creator>Elinav, Eran</creator><general>Elsevier Inc</general><general>Frontline Medical Communications Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4U-</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201712</creationdate><title>Microbiome at the Frontier of Personalized Medicine</title><author>Kashyap, Purna C. ; Chia, Nicholas ; Nelson, Heidi ; Segal, Eran ; Elinav, Eran</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-f8ee45bebcd7978baf0e4660263819816448deaef6f3d4184e1789329a5be4b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibiotics</topic><topic>Biomarkers</topic><topic>Diabetes</topic><topic>Diet</topic><topic>Disease</topic><topic>Disease prevention</topic><topic>Ecosystems</topic><topic>Feces</topic><topic>Forecasts and trends</topic><topic>Gastroenterology</topic><topic>Gastrointestinal Microbiome - physiology</topic><topic>Gastrointestinal Tract - microbiology</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Genome, Human</topic><topic>Genomes</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Irritable bowel syndrome</topic><topic>Medicine</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Microbiomes</topic><topic>Microbiota</topic><topic>Microbiota (Symbiotic organisms)</topic><topic>Next-generation sequencing</topic><topic>Nutrition research</topic><topic>Pathogenesis</topic><topic>Phenotypes</topic><topic>Precision Medicine</topic><topic>Probiotics</topic><topic>Prognosis</topic><topic>Therapeutic applications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kashyap, Purna C.</creatorcontrib><creatorcontrib>Chia, Nicholas</creatorcontrib><creatorcontrib>Nelson, Heidi</creatorcontrib><creatorcontrib>Segal, Eran</creatorcontrib><creatorcontrib>Elinav, Eran</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>University Readers</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kashyap, Purna C.</au><au>Chia, Nicholas</au><au>Nelson, Heidi</au><au>Segal, Eran</au><au>Elinav, Eran</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microbiome at the Frontier of Personalized Medicine</atitle><jtitle>Mayo Clinic proceedings</jtitle><addtitle>Mayo Clin Proc</addtitle><date>2017-12</date><risdate>2017</risdate><volume>92</volume><issue>12</issue><spage>1855</spage><epage>1864</epage><pages>1855-1864</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><abstract>The genomic revolution promises to transform our approach to treat patients by individualizing treatments, reducing adverse events, and decreasing health care costs. The early advances using this have been realized primarily by optimizing preventive and therapeutic approaches in cancer using human genome sequencing. The ability to characterize the microbiome, which includes all the microbes that reside within and upon us and all their genetic elements, using next-generation sequencing allows us to now incorporate this important contributor to human disease into developing new preventive and therapeutic strategies. In this review we highlight the importance of the microbiome in all aspects of human disease, including pathogenesis, phenotype, prognosis, and response to treatment, as well as their role as diagnostic and therapeutic biomarkers. We provide a role for next-generation sequencing in both precise microbial identification of infectious diseases and characterization of microbial communities and their function. Taken together, the microbiome is emerging as an integral part of precision medicine approach as it not only contributes to interindividual variability in all aspects of a disease but also represents a potentially modifiable factor that is amenable to targeting by therapeutics.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>29202942</pmid><doi>10.1016/j.mayocp.2017.10.004</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-6196
ispartof Mayo Clinic proceedings, 2017-12, Vol.92 (12), p.1855-1864
issn 0025-6196
1942-5546
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5730337
source MEDLINE; Alma/SFX Local Collection
subjects Antibiotics
Biomarkers
Diabetes
Diet
Disease
Disease prevention
Ecosystems
Feces
Forecasts and trends
Gastroenterology
Gastrointestinal Microbiome - physiology
Gastrointestinal Tract - microbiology
Gene expression
Genetic aspects
Genome, Human
Genomes
Health aspects
Humans
Infectious diseases
Irritable bowel syndrome
Medicine
Metabolism
Metabolites
Microbiomes
Microbiota
Microbiota (Symbiotic organisms)
Next-generation sequencing
Nutrition research
Pathogenesis
Phenotypes
Precision Medicine
Probiotics
Prognosis
Therapeutic applications
title Microbiome at the Frontier of Personalized Medicine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T20%3A56%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microbiome%20at%20the%20Frontier%20of%20Personalized%20Medicine&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=Kashyap,%20Purna%20C.&rft.date=2017-12&rft.volume=92&rft.issue=12&rft.spage=1855&rft.epage=1864&rft.pages=1855-1864&rft.issn=0025-6196&rft.eissn=1942-5546&rft_id=info:doi/10.1016/j.mayocp.2017.10.004&rft_dat=%3Cgale_pubme%3EA522584365%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1976352629&rft_id=info:pmid/29202942&rft_galeid=A522584365&rft_els_id=S0025619617307322&rfr_iscdi=true